Cyclerion Therapeutics (CYCN) AI Stock Analysis

• Market Cap: $9.63M
• Dividend Yield: N/A
• Average Volume (3M): 39.10K
• Price to Earnings (P/E): ―
• Beta (1Y): -0.58
• Revenue Growth: N/A
• EPS Growth: 86.52%
• Country: US
• Employees: 1
• Sector: Healthcare
• Sector Strength: 37
• Industry: Biotechnology
• EPS (TTM): -1.16
• Shares Outstanding: 3,210,094
• 10 Day Avg. Volume: 65,220
• 30 Day Avg. Volume: 39,097
• PEG Ratio: -0.58
• Price to Book (P/B): 0.96
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -3.07
• Enterprise Value/Market Cap: 0.68
• Enterprise Value/Revenue: 1.54
• Enterprise Value/Gross Profit: 3.16
• Enterprise Value/Ebitda: -0.33
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0

• Rating: 47 Neutral
• Price Target: ―

Cyclerion Therapeutics' overall stock score is primarily influenced by its financial difficulties, including consistent net losses and negative cash flows, despite having a solid equity position and no debt. The technical analysis provides a slightly more optimistic view with some bullish momentum, but the valuation remains unattractive due to ongoing financial challenges. The lack of earnings call or corporate events data means these factors did not affect the score.

Cyclerion Therapeutics Business Overview & Revenue Model

Company Description

Cyclerion Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovering, development, and commercialization of medicines for serious central nervous system (CNS) diseases. Its lead product candidate is CY6463, a CNS-penetrant, soluble guanylate cyclase (sGC) stimulator that is in Phase IIa trials for the treatment of mitochondrial encephalomyopathy, lactic acidosis, and stroke-like episodes, as well as Alzheimer's disease with vascular pathology; and Phase 1 trials diagnosed with schizophrenia in adults. It is also developing Praliciguat, an orally administered systemic sGC stimulator, which is in Phase II studies to treat resistant hypertension and diabetic nephropathy; Olinciguat, an orally administered vascular sGC stimulator that is in Phase II studies for the sickle cell disease; and CY3018 for the treatment of disorders of the CNS. It has license agreement with Akebia Therapeutics, Inc. for the development, manufacture, medical affairs, and commercialization of pharmaceutical products, including pharmaceutical compound, and other related products and forms. The company was incorporated in 2018 and is headquartered in Cambridge, Massachusetts.

How the Company Makes Money

Cyclerion Therapeutics makes money through the development and commercialization of its pharmaceutical products. As a clinical-stage company, its revenue streams can include research and development collaborations, licensing agreements, and potential milestone payments from partnerships. The company may also receive funding from grants or partnerships that support its research initiatives. Cyclerion’s financial performance is closely tied to the progress and success of its drug candidates in clinical trials, regulatory approvals, and eventual market entry. However, being in the clinical stage, the company might not have substantial revenue from product sales until its therapies receive regulatory approval and are commercially launched.

Cyclerion Therapeutics Financial Statement Overview

Summary

Cyclerion Therapeutics faces significant financial challenges with persistent net losses and negative cash flows, despite a strong equity position and no debt. Revenue growth has been inconsistent, and while the company maintains a high gross profit margin in revenue-generating years, operational and financial sustainability remains a concern. Continued focus on improving operational efficiency and cash flow generation is crucial for enhancing long-term financial health.

Income Statement

Cyclerion Therapeutics has shown volatility in revenue generation with a decline in revenue from 2019 to 2024. Although there was a revenue increase from 2023 to 2024, overall growth remains inconsistent. The gross profit margin has remained 100% in years with revenue, but the company has consistently posted negative net income and EBIT, indicating ongoing challenges in managing operating expenses and achieving profitability. The net profit margin has been negative, which underscores persistent losses.

Balance Sheet

Cyclerion's balance sheet reflects a strong equity position with zero debt in recent years, indicating potential stability in capital structure. However, the return on equity is negative due to consistent net losses, which is a concern for long-term sustainability. The equity ratio is relatively high due to low liabilities, suggesting reliance on equity financing but points to a lack of leverage for growth.

Cash Flow

The company is experiencing negative free cash flow, indicating challenges in generating cash from operations. The operating cash flow to net income ratio is negative due to significant cash outflows, and free cash flow has not shown growth, reflecting ongoing difficulties in achieving cash flow stability. This could impede future investment and operational flexibility.

Breakdown	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	2.00M	0.00	297.00K	3.32M	2.30M
Gross Profit	2.00M	0.00	232.00K	2.85M	2.30M
EBITDA	-3.63M	-12.59M	-18.18M	-55.20M	-81.27M
Net Income	-3.06M	-21.02M	-43.78M	-51.66M	-72.67M
Balance Sheet
Total Assets	9.57M	13.37M	18.08M	59.33M	115.38M
Cash, Cash Equivalents and Short-Term Investments	3.23M	7.57M	13.38M	53.96M	54.40M
Total Debt	0.00	0.00	0.00	0.00	45.73M
Total Liabilities	725.00K	2.09M	7.63M	11.09M	55.88M
Stockholders Equity	8.85M	11.29M	10.45M	48.25M	59.49M
Cash Flow
Free Cash Flow	-4.33M	-21.25M	-40.61M	-36.52M	-74.01M
Operating Cash Flow	-4.33M	-21.25M	-40.61M	-36.52M	-72.49M
Investing Cash Flow	0.00	10.40M	0.00	1.46M	18.00K
Financing Cash Flow	0.00	5.02M	29.00K	30.79M	28.09M

Cyclerion Therapeutics Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 3.02
• 50DMA: Negative
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CYCN, the sentiment is Negative. The current price of 3.02 is below the 20-day moving average (MA) of 3.20, below the 50-day MA of 3.11, and above the 200-day MA of 2.95, indicating a neutral trend. The MACD of 0.01 indicates Positive momentum. The RSI at 46.17 is Neutral, neither overbought nor oversold. The STOCH value of 29.83 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for CYCN.

Cyclerion Therapeutics Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	52 Neutral	$7.61B	0.10	-63.03%	2.08%	16.34%	0.32%
EVAX	48 Neutral	$3.76M	―	-205.75%	―	2552.29%	60.70%
CYCN	47 Neutral	$9.63M	―	-31.48%	―	―	86.52%
CARM	46 Neutral	$16.48M	―	-362.79%	―	32.45%	39.31%
HCWB	46 Neutral	$10.67M	―	-9999.00%	―	-63.20%	15.71%
APRE	40 Underperform	$10.68M	―	-59.80%	―	157.63%	40.52%
TSBX	34 Underperform	$8.37M	―	-126.03%	―	-100.00%	-27.44%

Cyclerion Therapeutics Corporate Events

Cyclerion Therapeutics Secures Funding and Expands CNS Focus

Cyclerion Therapeutics has renegotiated its praliciguat license agreement with Akebia, securing $1.75 million in upfront and near-term payments while reducing operating expenses to focus on building its CNS pipeline. Additionally, Cyclerion entered into a license option agreement for olinciguat with CVCO Therapeutics, marking significant steps in monetizing its legacy assets and positioning itself for future growth by acquiring new CNS assets.